You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

PROCOMP Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Procomp, and what generic alternatives are available?

Procomp is a drug marketed by Jubilant Cadista and is included in one NDA.

The generic ingredient in PROCOMP is prochlorperazine maleate. There are twenty-one drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the prochlorperazine maleate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Procomp

A generic version of PROCOMP was approved as prochlorperazine maleate by NOVITIUM PHARMA on June 13th, 2022.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PROCOMP?
  • What are the global sales for PROCOMP?
  • What is Average Wholesale Price for PROCOMP?
Summary for PROCOMP
US Patents:0
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 14
DailyMed Link:PROCOMP at DailyMed
Drug patent expirations by year for PROCOMP
Pharmacology for PROCOMP
Drug ClassPhenothiazine

US Patents and Regulatory Information for PROCOMP

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Jubilant Cadista PROCOMP prochlorperazine maleate TABLET;ORAL 040268-001 Feb 27, 1998 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Jubilant Cadista PROCOMP prochlorperazine maleate TABLET;ORAL 040268-002 Feb 27, 1998 AB RX No Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

PROCOMP Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory in the Prescription Drug Market: Lessons for PROCOMP

Introduction

The prescription drug market is a complex and dynamic sector, influenced by various factors such as competition, innovation, regulatory policies, and patient needs. Understanding these dynamics is crucial for any drug, including PROCOMP, to navigate the market successfully. Here, we will delve into the key aspects of the prescription drug market and how they impact the financial trajectory of drugs like PROCOMP.

Competition in Prescription Drug Markets

Competition is a pivotal factor in the prescription drug market, significantly affecting drug prices and accessibility. Studies have shown that drugs with fewer or only one manufacturer tend to have higher prices compared to those with multiple manufacturers[1].

  • Small Molecule Drugs vs. Biological Products: The market for small molecule drugs and biological products differs significantly. In 2022, 43% of small molecule drugs had only one manufacturer, while 32% had six or more manufacturers. This competition led to a decrease in the price per small molecule drug over time[1].
  • Specialty Drugs: Specialty drugs, which include both small molecule and biological products, saw an increase in spending per prescription despite a decrease in the number of prescriptions. This indicates that higher prices drove the spending growth in this segment[1].

Impact of Competition on Drug Prices

Competition among brand-name drugs, generics, and biosimilars can significantly reduce drug costs.

  • Brand-to-Brand Competition: The introduction of multiple brand-name competitor drugs can lead to lower costs. For example, in the hepatitis C virus (HCV) market, the entry of multiple brand-name drugs resulted in lower net costs and significant savings for patients and payers[4].
  • Negotiation Power: Pharmacy benefit managers (PBMs) can negotiate deeper discounts from drug manufacturers when there are multiple competitor products available, benefiting patients and reducing overall costs[4].

Trends in Prescription Drug Spending

Prescription drug spending has seen rapid growth over the past few decades, driven by several factors.

  • Historical Growth: Since the 1990s, prescription drug spending has increased significantly, with annual growth rates ranging from 11.9% to 21.9% per capita[2].
  • Recent and Forecasted Trends: After a slight decrease in 2020, per capita retail prescription drug spending increased in 2021. Projections suggest moderate growth in the next decade, with spending expected to plateau due to policy changes and inflation rebates[5].

Factors Driving Spending Growth

Several factors contribute to the growth in prescription drug spending.

  • New Drugs and Pipeline: New drugs awaiting FDA approval are expected to drive a significant portion of spending growth. For instance, central nervous system drugs and cardiovascular drugs are projected to account for a substantial share of future spending increases[2].
  • Chronic Diseases and Global Demand: The escalating global burden of chronic diseases, such as cancer and antimicrobial resistance, fuels the demand for new and innovative drugs. This demand is expected to drive the pharmaceutical market revenue to exceed $1.4 trillion by 2028[3].

Investment Trends in Pharmaceutical Research

The development of new drugs is a costly and risky endeavor.

  • Cost and Timeline: The average cost of bringing a new drug to market is approximately $2.6 billion, with a development timeline of 10 to 15 years. The success rate for drug candidates entering clinical trials is only about 10%[3].
  • Blockbuster Drugs: Successful drugs, known as blockbuster drugs, can generate significant revenue streams. However, the development process is fraught with scientific and regulatory hurdles[3].

Balancing Profit and Public Health

Pharmaceutical companies must balance the need for profit with the imperative of public health.

  • Antimicrobial Resistance: The development of new antibiotics to combat drug-resistant infections is crucial but comes with significant financial risks. Initiatives like the AMR Action Fund aim to incentivize investment in this area[3].
  • Neglected Tropical Diseases: Addressing neglected tropical diseases also requires substantial investment, often with uncertain market returns[3].

Regulatory and Policy Impacts

Regulatory policies can significantly influence the financial trajectory of prescription drugs.

  • Inflation Reduction Act: Provisions in the Inflation Reduction Act are expected to reduce out-of-pocket drug spending and aggregate drug costs through price negotiations and inflation rebates. This could lead to a 20% reduction in aggregate drug costs and a reduction in the federal deficit[5].

Key Takeaways for PROCOMP

For a drug like PROCOMP, understanding these market dynamics is crucial:

  • Competition: Encourage competition by ensuring multiple manufacturers or competitor products are available to reduce prices and increase accessibility.
  • Innovation: Invest in R&D to address unmet medical needs and capitalize on emerging market opportunities.
  • Regulatory Policies: Stay abreast of regulatory changes and policy initiatives that can impact drug pricing and spending.
  • Public Health Needs: Balance profit goals with public health imperatives, especially in areas like antimicrobial resistance and chronic diseases.

FAQs

Q1: How does competition affect drug prices in the prescription drug market? Competition among multiple manufacturers or competitor products can significantly reduce drug prices. When there are more competitors, pharmacy benefit managers can negotiate deeper discounts, leading to lower costs for patients and payers[1][4].

Q2: What are the main drivers of spending growth in the prescription drug market? Spending growth is driven by factors such as new drugs entering the market, increased spending per prescription, and the rising incidence of chronic diseases. New drugs in the pipeline and changes in utilization patterns also contribute to this growth[2][5].

Q3: How do regulatory policies impact the financial trajectory of prescription drugs? Regulatory policies, such as those outlined in the Inflation Reduction Act, can reduce out-of-pocket drug spending and aggregate drug costs through price negotiations and inflation rebates. These policies can also influence the overall spending trends in the prescription drug market[5].

Q4: What are the challenges and opportunities in pharmaceutical research and development? The development of new drugs is costly and risky, with a high attrition rate and long development timelines. However, successful drugs can generate substantial revenue streams. Pharmaceutical companies must balance these risks with the need to address unmet medical needs and public health imperatives[3].

Q5: How does the global burden of chronic diseases impact the pharmaceutical market? The escalating global burden of chronic diseases, such as cancer and antimicrobial resistance, fuels the demand for new and innovative drugs. This demand is expected to drive the pharmaceutical market revenue to exceed $1.4 trillion by 2028, making it a significant market opportunity for pharmaceutical companies[3].

Sources

  1. Competition in Prescription Drug Markets, 2017-2022 - ASPE
  2. Explaining the Growth in Prescription Drug Spending: A Review of Recent Studies - ASPE
  3. Investment Trends in Pharmaceutical Research - DrugBank Blog
  4. The Upside of More Drugs: How Competition Among Brand-Name Drugs Works for Patients - PCMA
  5. What are the recent and forecasted trends in prescription drug spending? - Health System Tracker

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.